Trial · NCT03126110
Results by group178
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 178
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Phase 1: Number of Participants With Any Treatment-emergent Adverse Event (TEAE) | Phase 1 Group A: INCAGN01876 1.0 mg/kg Q2W + Nivolumab 240 mg Q2W | 4 | Participants | ||
| Phase 1: Number of Participants With Any Treatment-emergent Adverse Event (TEAE) | Phase 1 Group A: INCAGN01876 3.0 mg/kg Q2W + Nivolumab 240 mg Q2W | 4 | Participants | ||
| Phase 1: Number of Participants With Any Treatment-emergent Adverse Event (TEAE) | Phase 1 Group A: INCAGN01876 5.0 mg/kg Q2W + Nivolumab 240 mg Q2W | 5 | Participants | ||
| Phase 1: Number of Participants With Any Treatment-emergent Adverse Event (TEAE) | Phase 1 Group A: INCAGN01876 10.0 mg/kg Q2W + Nivolumab 240 mg Q2W | 4 | Participants | ||
| Phase 1: Number of Participants With Any Treatment-emergent Adverse Event (TEAE) | Phase 1 Group B: INCAGN01876 1.0 mg/kg Q2W, Then Nivolumab 240 mg Q2W | 5 | Participants | ||
| Phase 1: Number of Participants With Any Treatment-emergent Adverse Event (TEAE) | Phase 1 Group B: INCAGN01876 3.0 mg/kg Q2W, Then Nivolumab 240 mg Q2W | 4 | Participants | ||
| Phase 1: Number of Participants With Any Treatment-emergent Adverse Event (TEAE) | Phase 1 Group B: INCAGN01876 5.0 mg/kg Q2W, Then Nivolumab 240 mg Q2W | 4 | Participants | ||
| Phase 1: Number of Participants With Any Treatment-emergent Adverse Event (TEAE) | Phase 1 Group C: INCAGN01876 1.0 mg/kg Q2W + Ipilimumab 1 mg/kg Q6W | 4 | Participants | ||
| Phase 1: Number of Participants With Any Treatment-emergent Adverse Event (TEAE) | Phase 1 Group C: INCAGN01876 3.0 mg/kg Q2W + Ipilimumab 1 mg/kg Q6W | 7 | Participants | ||
| Phase 1: Number of Participants With Any Treatment-emergent Adverse Event (TEAE) | Phase 1 Group C: INCAGN01876 5.0 mg/kg Q2W + Ipilimumab 1 mg/kg Q6W | 3 | Participants | ||
| Phase 1: Number of Participants With Any Treatment-emergent Adverse Event (TEAE) | Phase 1 Group D: INCAGN01876 1.0 mg/kg + Nivolumab 3 mg/kg + Ipilimumab 1 mg/kg | 6 | Participants | ||
| Phase 2: Objective Response Rate (ORR) Per RECIST v1.1 | Phase 2 Group C2 PD-1/PD-L1 RM: INCAGN01876 300 mg + Ipilimumab 1 mg/kg | 0.0 | Percentage of Participants | ||
| Phase 2: Objective Response Rate (ORR) Per RECIST v1.1 | Phase 2 Group F GC: INCAGN01876 300 mg + Nivolumab 240 mg | 0.0 | Percentage of Participants | ||
| Phase 2: Objective Response Rate (ORR) Per RECIST v1.1 | Phase 2 Group F SCCHN INCAGN01876 300 mg + Nivolumab 240 mg | 23.9 | Percentage of Participants | ||
| Phase 2: Objective Response Rate (ORR) Per RECIST v1.1 | Phase 2 Group F CC: INCAGN01876 300 mg + Nivolumab 240 mg | 16.7 | Percentage of Participants | ||
| Phase 2: Objective Response Rate (ORR) Per RECIST v1.1 | Phase 2 Group F PD-1/PD-L1 RM: INCAGN01876 300 mg + Nivolumab 240 mg | 0.0 | Percentage of Participants | ||
| Phase 2: Objective Response Rate (ORR) Per RECIST v1.1 | Phase 2 Group F Biopsy: INCAGN01876 300 mg + Nivolumab 240 mg | 0.0 | Percentage of Participants | ||
| Phase 1: ORR Per RECIST v1.1 | Phase 1 Group A: INCAGN01876 1.0 mg/kg Q2W + Nivolumab 240 mg Q2W | 25.0 | Percentage of Participants | ||
| Phase 1: ORR Per RECIST v1.1 | Phase 1 Group A: INCAGN01876 3.0 mg/kg Q2W + Nivolumab 240 mg Q2W | 0.0 | Percentage of Participants | ||
| Phase 1: ORR Per RECIST v1.1 | Phase 1 Group A: INCAGN01876 5.0 mg/kg Q2W + Nivolumab 240 mg Q2W | 20.0 | Percentage of Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03126110/results